Arrowhead Pharmaceuticals, Inc.

416 articles with Arrowhead Pharmaceuticals, Inc.

• Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-APOC3 for Treatment of Severe Hypertriglyceridemia

  6/3/2021

  Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patient in AROAPOC3-2001, a Phase 2b clinical study of ARO-APOC3, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with severe hypertriglyceridemia (SHTG).

•  Arrowhead Pharmaceuticals to Participate in Upcoming Conferences - June 02, 2021

  6/2/2021

  Arrowhead Pharmaceuticals Inc. announced that it is scheduled to participate in the following upcoming events

• Arrowhead Earns $10 Million Option Exercise Fee

  5/18/2021

  Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that Janssen Pharmaceuticals, Inc., (Janssen) part of the Janssen Pharmaceutical Companies of Johnson & Johnson, has delivered written notice of its intent to exercise its option right for ARO-JNJ1.

• Arrowhead Pharmaceuticals to Participate in Upcoming Conferences - May 12, 2021

  5/12/2021

  Arrowhead Pharmaceuticals Inc. announced that it is scheduled to participate in the following upcoming events

• Arrowhead Pharmaceuticals Reports Fiscal 2021 Second Quarter Results

  5/4/2021

  Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal second quarter ended March 31, 2021

• Arrowhead Announces Improvement in Fibrosis after ARO-AAT Treatment in Patients with Alpha-1 Liver Disease

  4/28/2021

  Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced positive interim 48-week liver biopsy results from the AROAAT2002 study, an open-label Phase 2 clinical study of ARO-AAT, the company’s second generation investigational RNA interference (RNAi) therapeutic being co-developed with Takeda Pharmaceutical Company Limited ("Takeda”) as a treatment for the rare genetic liver disease

• Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results

  4/16/2021

  Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 4, 2021, at 4:30 p.m. ET to discuss its financial results for the fiscal second quarter ended March 31, 2021.

• Arrowhead Announces ARO-DUX4 as First Muscle Targeted RNAi Candidate Using TRiMTM Platform

  4/15/2021

  Arrowhead Pharmaceuticals, Inc. (RE )--NASDAQ: ARWR) today announced ARO-DUX4 as Arrowhead’s first muscle targeted investigational RNAi therapeutic candidate to utilize its proprietary Targeted RNAi Molecule (TRIM TM ) platform.

• Arrowhead Pharmaceuticals Files IND to Begin Phase 2b Study of ARO-APOC3 in Patients with Severe Hypertriglyceridemia

  3/1/2021

  Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for ARO-APOC3, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with hypertriglyceridemia.

• Arrowhead Pharmaceuticals Reports Fiscal 2021 First Quarter Results

  2/4/2021

  Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal first quarter ended December 31, 2020. The company is hosting a conference call at 4:30 p.m. EST to discuss results. Conference Call and Webcast Details

• Arrowhead Pharmaceuticals Files IND for Phase 2b Study of ARO-ANG3 for Treatment of Mixed Dyslipidemia

  1/25/2021

  Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for a Phase 2b dose-finding clinical study of ARO-ANG3

• Arrowhead Pharmaceuticals Reported Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)

  12/7/2020

  Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on December 4, 2020, the Compensation Committee of the Board of Directors approved “inducement” grants to 27 new employees under Rule 5635(c)(4) of the NASDAQ Marketplace Rules. The option grants entitle employees, in aggregate, to purchase up to 145,000 shares of common stock and receive up

• Arrowhead Pharmaceuticals to Participate in Upcoming Conferences - Nov 30, 2020

  11/30/2020

  Arrowhead Pharmaceuticals, Inc. announced that it is scheduled to participate in the following upcoming events

• Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda

  11/25/2020

  Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the collaboration and license agreement between Arrowhead and Takeda Pharmaceutical Company Limited announced on October 8, 2020, has now closed

• Arrowhead Pharmaceuticals Reports Fiscal 2020 Year End Results

  11/23/2020

  Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal year ended September 30, 2020.

• Arrowhead Presents New Clinical Data on Cardiometabolic Pipeline at AHA 2020

  11/13/2020

  - ARO-APOC3 achieved triglyceride reductions of 74-92% - ARO-ANG3 achieved triglyceride reductions of 29-75% and LCL-C reductions of 29-35% - Company to host upcoming KOL webinars on ARO-APOC3 and ARO-ANG3

• Arrowhead Interim Clinical Data Demonstrate ARO-AAT Treatment Improved Multiple Biomarkers of Alpha-1 Liver Disease

  11/13/2020

  Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced positive interim clinical data from AROAAT2002, an open-label Phase 2 clinical study of ARO-AAT, the company’s second-generation investigational RNA interference (RNAi) therapeutic being developed as a treatment for the rare genetic liver disease associated with alpha-1 antitrypsin deficiency (AATD).

• Arrowhead Pharmaceuticals to Participate in Upcoming Conferences

  11/9/2020

  Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: The Liver Meeting Digital Experience, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD) – November 13-16, 2020 Title: ARO-AAT Reduces Serum and Intra-hepatic Z-AAT Protein in PIZZ Alpha-1 Antitrypsin Deficient Patients with Liver Disease Lead

• Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinars on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3

  11/4/2020

  Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that on November 18, and November 19, 2020, it will host two key opinion leader (KOL) webinars to discuss the company’s two investigational RNA interference (RNAi) based cardiometabolic candidates, ARO-APOC3 and ARO-ANG3. Arrowhead will also present data from Phase 1/2 clinical studies of ARO-APOC3 and ARO-ANG3 at the American Heart Association (AHA) Scientifi

• Arrowhead Pharmaceuticals to Webcast Fiscal 2020 Year End Results

  11/2/2020

  Arrowhead Pharmaceuticals Inc.(NASDAQ: ARWR) today announced that it will host a webcast and conference call on November 23, 2020, at 4:30 p.m. EST to discuss its financial results for the fiscal year ended September 30, 2020.